CK Life Sciences Int'l. (Holdings) Yönetim

Yönetim kriter kontrolleri 2/4

CK Life Sciences Int'l. (Holdings) CEO'su Lance Richard Lee Yuen, Sep2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.024% doğrudan sahiptir ve bu hisselerin değeri HK$ 931.47K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 14.3 yıl ve 6.1 yıldır.

Anahtar bilgiler

Lance Richard Lee Yuen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	14.3yrs
Yönetim Kurulu ortalama görev süresi	6.1yrs

Son yönetim güncellemeleri

Recent updates

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Oct 04

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

May 03

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Apr 25

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Mar 26

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Sep 27

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Sep 16

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Aug 21

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

Apr 14

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Mar 18

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

Feb 01

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

Jan 04

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Dec 09

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

Nov 18

CEO

Lance Richard Lee Yuen (59 yo)

less than a year

Görev süresi

Mr. Lance Richard Lee Yuen is Executive Director, Vice President & Chief Executive Officer of CK Life Sciences Int'l. (Holdings) Inc. from September 20, 2024. Mr. Yuen joined the Group in September 2024.M...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tzar Kuoi Li	Executive Chairman	22.7yrs	HK$125.00k	0.023% HK$ 911.2k
Hing Lam Kam	President & Executive Director	22.5yrs	HK$2.58m	0.065% HK$ 2.5m
Edmond Tak Chuen IP	Senior VP	no data	HK$1.60m	0.023% HK$ 911.2k
Kean Meng Toh	VP, Chief Scientific Officer & Executive Director	6.1yrs	HK$6.13m	Veri yok
Lance Richard Lee Yuen	VP, CEO & Executive Director	less than a year	Veri yok	0.024% HK$ 931.5k
Wun Lam Wong	Chief Financial Officer	no data	Veri yok	Veri yok
Pak To Wu	Chief Operating Officer of Global Operations	no data	Veri yok	Veri yok
Yau Wong	Senior Manager of Human Resources & Administration	no data	Veri yok	Veri yok
Ching Sze Chiu	General Counsel	no data	Veri yok	Veri yok
Sze Ho	Vice President of Corporate Development	no data	Veri yok	Veri yok
Wai Che Tong Barnes	Chief Corporate Affairs Officer	no data	Veri yok	Veri yok
Eirene Yeung	Company Secretary	22.9yrs	Veri yok	Veri yok

14.3yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim: 775 'un yönetim ekibi deneyimli ve deneyimlidir ( 14.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tzar Kuoi Li	Executive Chairman	22.7yrs	HK$125.00k	0.023% HK$ 911.2k
Hing Lam Kam	President & Executive Director	no data	HK$2.58m	0.065% HK$ 2.5m
Edmond Tak Chuen IP	Senior VP	no data	HK$1.60m	0.023% HK$ 911.2k
Kean Meng Toh	VP, Chief Scientific Officer & Executive Director	6.1yrs	HK$6.13m	Veri yok
Lance Richard Lee Yuen	VP, CEO & Executive Director	less than a year	Veri yok	0.024% HK$ 931.5k
Eva Kwok	Independent Non-Executive Director	22.5yrs	HK$100.00k	0.0021% HK$ 81.0k
Keith Frankel	Co-Chairman of Vitaquest International LLC	no data	Veri yok	Veri yok
Peter Peace Tulloch	Non-Executive Director	22.7yrs	HK$75.00k	0.011% HK$ 425.1k
Ying Choi Yu	Deputy Chairman	less than a year	HK$14.79m	0.023% HK$ 911.2k
Kai Cheong Kwan	Independent Non-executive Director	9.8yrs	HK$155.00k	Veri yok
Donald Jeffrey Roberts	Independent Non-Executive Director	4.4yrs	HK$205.00k	Veri yok
Joseph Paul Tighe	Independent Non-Executive Director	5.5yrs	HK$205.00k	Veri yok

6.1yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 775 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 03:18
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

CK Life Sciences Int'l., (Holdings) Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jayaprabha Dhavale	Virtua Research Inc.

CK Life Sciences Int'l. (Holdings) Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

VP, CEO & Executive Director recently bought HK$969k worth of stock

CK Life Sciences Int'l., (Holdings) Inc Announces Director Changes

CK Life Sciences Int'l., (Holdings) Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

CK Life Sciences Int'l., (Holdings) Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee

Less than half of directors are independent

Recent updates

Now 23% undervalued

VP, CEO & Executive Director recently bought HK$969k worth of stock

Now 21% undervalued

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CK Life Sciences Int'l., (Holdings) Inc Announces Director Changes

First half 2024 earnings released: EPS: HK$0 (vs HK$0.004 in 1H 2023)

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2024 Results on Aug 13, 2024

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

CK Life Sciences Int'l., (Holdings) Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

New minor risk - Financial data availability

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Ck Life Sciences Int'l., (Holdings) Inc. Announces Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-Targeting Prame and PD-L1

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.007 in 1H 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: HK$0.014 (vs HK$0.017 in FY 2021)

Less than half of directors are independent

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

CK Life Sciences Int'l., (Holdings) Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee

First half 2022 earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2022 Results on Aug 02, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.01 per share

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2021 Results on Mar 15, 2022

Now 20% undervalued after recent price drop

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.009 in 1H 2020)

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Upcoming dividend of HK$0.01 per share

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

Ck Life Sciences Int'l., (Holdings) Inc. Recommends Final Dividend for the Year Ended 31 December 2020, Payable on May 31, 2021

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

New 90-day low: HK$0.86

CK Life Sciences Int'l., (Holdings) Inc. Announces Directors Changes

New 90-day low: HK$0.89

CK Life Sciences Int'l., (Holdings) Inc. Announces Executive Changes

First half earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report Q2, 2020 Results on Aug 04, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları